![]() |
市場調查報告書
商品編碼
1500282
肺炎鏈球菌疫苗市場:按類型、適應症、年齡層、分佈分類 - 2024-2030 年全球預測Pneumococcal Vaccine Market by Type (Conjugate Vaccines, Polysaccharide Vaccines), Indication (Bronchitis, Meningitis, Pneumonia), Age Group, Distribution - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年肺炎鏈球菌疫苗市場規模為107.3億美元,預計2024年將達115.6億美元,2030年將達183億美元,複合年成長率為7.92%。
肺炎鏈球菌疫苗旨在預防鏈球菌引起的感染疾病。這些感染疾病的範圍從耳朵和鼻竇感染疾病到肺炎、腦膜炎和血液感染疾病等嚴重。這種疫苗對於兒童、老年人和患有某些健康狀況且更容易感染這種疾病的人來說至關重要。隨著世界人口老化以及越來越多的人面臨慢性疾病的風險,肺炎球菌疾病的盛行率不斷增加,從而增加了對肺炎球菌疫苗的需求。政府和國際衛生組織對肺炎球菌疫苗的支持正在推動市場成長。這些疫苗通常被納入國家免疫計劃中,因為它們可以降低細菌感染疾病的發生率,尤其是兒童和老年人。人們對免疫重要性的認知不斷提高,加上公共衛生宣傳活動和教育計畫的加強,正在支持肺炎鏈球菌疫苗市場的成長。高開發成本和複雜的疫苗儲存和處理要求阻礙了市場成長。疫苗技術的改進以及針對不同菌株提供廣泛保護的結合疫苗的持續開發預計將為肺炎球菌疫苗市場創造機會。
主要市場統計 | |
---|---|
基準年[2023] | 107.3億美元 |
預測年份 [2024] | 115.6億美元 |
預測年份 [2030] | 183億美元 |
複合年成長率(%) | 7.92% |
區域洞察
美國擁有發達的醫療保健系統,對疫苗接種方案(包括肺炎球菌疫苗接種,尤其是嬰幼兒和老年人)的認知度很高,並且是一個高度發展的新興市場。將免疫計畫納入公共衛生政策等政策舉措將進一步刺激疫苗接種率。在亞太地區,由於政府在經濟開拓、醫療基礎設施和疫苗接種方面的政策存在差異,各國的市場動態差異很大。日本、澳洲和韓國等國家由於有利的醫療保健政策和預防保健意識的提高,肺炎鏈球菌疫苗接種覆蓋率很高。另一方面,由於醫療基礎設施改善、中等收入群體增加以及政府推廣肺炎鏈球菌感染疫苗接種,印度、日本、中國等新興國家的疫苗接種率正在迅速上升。歐洲是肺炎球菌疫苗的強大市場,擁有全面的醫療保健系統和廣泛的疫苗接種覆蓋率。由於醫療保健能力不同以及政府對免疫計劃的支持程度不同,中東和非洲的疫苗普及參差不齊。與東歐國家相比,西歐國家的疫苗接種率普遍較高。同時,非洲和中東部分地區仍在繼續努力改善疫苗取得和疫苗接種率,這通常得到國際衛生組織的支持。
FPNV定位矩陣
FPNV 定位矩陣對於評估肺炎鏈球菌疫苗市場供應商的市場定位至關重要。此矩陣提供了對供應商的全面評估,並檢驗了與商務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果,供應商被分為代表其成功程度的四個像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對肺炎鏈球菌疫苗市場供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻,您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他關鍵指標。此外,該分析還提供了對該行業競爭性質的寶貴見解,包括在研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊,供應商可以做出更明智的決策並製定有效的策略,以在市場競爭中保持領先地位。
策略分析與建議
策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對當前肺炎球菌疫苗市場地位的全面評估使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析,以確定核心優勢和需要改進的領域。
[184 Pages Report] The Pneumococcal Vaccine Market size was estimated at USD 10.73 billion in 2023 and expected to reach USD 11.56 billion in 2024, at a CAGR 7.92% to reach USD 18.30 billion by 2030.
The pneumococcal vaccine is designed to protect against infections caused by the streptococcus pneumoniae bacteria. These infections range from ear and sinus infections to more severe illnesses, including pneumonia, meningitis, and bloodstream infections. The vaccine is essential for children, the elderly, and individuals with certain health conditions that make them more vulnerable to disease. With the increasing prevalence of pneumococcal diseases as global populations age and more individuals are at risk of chronic diseases, there is an increased need for pneumococcal vaccines. The availability of support from governments and international health organizations for pneumococcal vaccines is driving the market growth. These vaccines are often included in national immunization schedules to reduce the incidence of bacterial infections, especially in children and the elderly. Growing awareness about the importance of immunizations, bolstered by public health campaigns and education programs, supports the growth of the pneumococcal vaccine market. The high development cost and complex vaccine storage and handling requirements hamper the market growth. Rising improvements in vaccine technology and the development of conjugate vaccines that provide broader protection against various strains of bacteria are expected to create opportunities for the pneumococcal vaccine market.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 10.73 billion |
Estimated Year [2024] | USD 11.56 billion |
Forecast Year [2030] | USD 18.30 billion |
CAGR (%) | 7.92% |
Regional Insights
America shows a highly developing pneumococcal vaccine market with well-structured healthcare systems and high awareness regarding vaccination protocols, including pneumococcal vaccination, especially for infants and the elderly segment of the population. Policy initiatives, including immunization programs integrated into public health policy, further stimulate vaccine coverage. In APAC, the market dynamics vary widely across countries due to differences in economic development, healthcare infrastructure, and government policies related to vaccinations. Countries such as Japan, Australia, and South Korea exhibit higher adoption rates for pneumococcal vaccines, driven by favorable healthcare policies and a rising awareness of preventive healthcare. Meanwhile, emerging economies such as India, Japan, and China are experiencing rapid growth in vaccine uptake due to improving healthcare infrastructure, increasing middle-class populations, and government immunization drives against pneumococcal diseases. Europe is a strong market for pneumococcal vaccines, supported by comprehensive healthcare systems and wide vaccine coverage. The Middle East and Africa show varied vaccine adoption rates due to contrasting healthcare capabilities and varying levels of government support for immunization programs. Western European countries generally report higher vaccination rates compared to Eastern European nations. Meanwhile, in Africa and some parts of the Middle East, efforts are ongoing to enhance vaccine access and inoculation rates, often supported by international health organizations.
Market Insights
The market dynamics represent an ever-changing landscape of the Pneumococcal Vaccine Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Pneumococcal Vaccine Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Pneumococcal Vaccine Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
FDA Approves Merck's New Pneumococcal Vaccine Targeting Broad Protection
The U.S. Food and Drug Administration (FDA) approved Merck's innovative 21-valent pneumococcal conjugate pneumococcal vaccine, designed to offer protection against a comprehensive range of pneumococcal disease strains. This approval underscores a significant advancement in public health, promising enhanced protection for individuals, especially vulnerable populations such as older people and those with compromised immune systems. Merck's vaccine, which has demonstrated efficacy in preventing infections caused by numerous strains of pneumococcal bacteria, aims to reduce the incidence and severity of pneumococcal diseases such as pneumonia, meningitis, and bloodstream infections. [Published On: 2023-12-20]
Vaxcyte Bolsters Global Supply Chain with Enhanced Lonza Collaboration for Pneumococcal Vaccine Production
Vaxcyte, Inc. is expanding its collaboration with Lonza, a key global player in the pharmaceutical and biotech manufacturing sector, to elevate the production of VAX-24, its 24-valent pneumococcal conjugate vaccine candidate. This strategic partnership aims to reinforce Vaxcyte's manufacturing capabilities to meet global commercial demands, anticipating the transition into the pivotal Phase 3 vaccine trial. This collaboration underscores both companies' commitment to addressing the wide-ranging pneumococcal disease threat with a next-generation vaccine that could significantly impact public health worldwide. [Published On: 2023-10-16]
FDA Approves Pfizer's Prevnar 20 a Significant Advancement in Pneumococcal Disease Prevention
The U.S. Food and Drug Administration (FDA) has recently approved Prevnar 20, a novel 20-valent pneumococcal conjugate vaccine developed by Pfizer. This approval marks a significant milestone in preventing pneumococcal diseases, as Prevnar 20 is designed to protect against twenty pneumococcal serotypes responsible for most pneumococcal disease cases and pneumonia. The vaccine is authorized for use in adults aged 18 years and older, offering enhanced coverage and aiming to improve public health outcomes by reducing the incidences of these severe infections. This development is particularly timely, considering the substantial health burden pneumococcal diseases place on individuals and healthcare systems globally. [Published On: 2023-04-27]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Pneumococcal Vaccine Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Pneumococcal Vaccine Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Biological E. Limited, Biovac, CSL Limited, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Incepta Pharmaceuticals Ltd., Lonza AG, Merck & Co., Inc., Panacea Biotec Limited, Pfizer, Inc., Sanofi SA, Serum Institute of India Pvt. Ltd., Vaxcyte Inc., and Walvax Biotechnology Co., Ltd..
Market Segmentation & Coverage